New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:31 EDTCLDX, INCY, GILD, NPSPOppenheimer sees opportunities following biotech decline
After biotech stocks declined on Friday, Oppenheimer believes that the weakness in the sector has created a buying opportunity. The firm identifies Celldex (CLDX), Incyte (INCY) and NPS Pharmaceuticals (NPSP) as interesting biotech names. WHAT'S NEW: On Friday, biotech investors were concerned by a letter sent by several members of Congress to Gilead (GILD) regarding the price of its Hepatits C drug, Sovaldi, Oppenheimer analyst Dr. Boris Peaker wrote in a note to investors. However, the biotech sector's strong pricing power is unlikely to be curtailed In the near-term, Peaker believes. Since competing drugs are priced at similar levels as Sovaldi, Congress would have to lower the drugs' prices through legislation, which is unlikely to occur, Peaker forecast. Celldex's stock is attractive since its top drugs are very innovative, face no direct competition, are wholly owned by the company, and are unlikely to have biosimilars, Peaker wrote. Meanwhile, Incyte's Jakafi, a treatment for Myelofibrosis, could be used as a treatment for solid tumors following additional studies, the analyst forecast. Additionally, Jakafi is "highly innovative," and has not experienced any pricing pressures, the analyst stated. NPS' two major products, Gattex and Natpara, are both orphan drugs that provide significant benefits to patients and do not have any looming competition, Peaker said, adding that Gattex's U.S. sales should continue to be strong. Gattex is used to treat short bowel syndrome, while Natpara is supposed to treat hypoparathyroidism. Oppenheimer has Outperform ratings on all the stocks named. PRICE ACTION: In mid-morning trading, Gilead fell 2.3% to $70.40, Celldex gave back 6.6% to $20.10, Incyte tumbled 5.8% to $56, and NPS sank 5.8% to $28.35.
News For GILD;CLDX;NPSP;INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
10:10 EDTINCYAnalyst calls sharp pullback in biotech stocks 'misguided'
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TWTR FB KRFT BIDU TSLA CELG NFLX FCAU
06:45 EDTINCYBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
05:34 EDTGILDGilead Sovaldi approved in Japan
Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved Sovaldi, a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus, or HCV, infection with or without compensated cirrhosis. Sovaldi is indicated for use in combination with ribavirin, or RBV, for 12 weeks. Sovaldi is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection. Sovaldi is also the first product to be marketed by Gilead in Japan.
March 25, 2015
16:00 EDTGILDOptions Update; March 25, 2015
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA KRFT FB BIDU GPRO V GILD NFLX
March 24, 2015
08:00 EDTGILDGilead shares should be bought on weakness, says Bernstein
Subscribe for More Information
March 23, 2015
16:01 EDTGILDOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
11:45 EDTGILDGilead defended after slide following death of Hep C patient on heart drug
Subscribe for More Information
11:32 EDTGILDStocks with call strike movement; GILD CELG
Gilead (GILD) August 115 call option implied volatility increased 5% to 27, Celgene (CELG) July 140 call option implied volatility increased 3% to 28 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:44 EDTGILDGilead volatility low into FDA hepatitis C drug warning
Subscribe for More Information
08:23 EDTGILDGilead weakness a buying opportunity, says RW Baird
Subscribe for More Information
07:40 EDTGILDGilead weakness on FDA warning would be buying opportunity, says Wells Fargo
Subscribe for More Information
06:08 EDTGILDGilead implied volatility of 23 at lower end of index mean range
Subscribe for More Information
March 22, 2015
15:05 EDTGILDGilead warns after hepatitis C patient taking heart drug dies, Bloomberg says
Gilead said in an e-mailed drug warning to health-care providers on Friday that nine patients taking its hepatitis C drugs Harvoni or Sovaldi along with the heart treatment amiodarone developed abnormally slow heartbeats and one died of cardiac arrest, says Bloomberg. Reference Link
March 20, 2015
16:00 EDTGILDOptions Update; March 20, 2015
Subscribe for More Information
15:02 EDTGILDAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
March 19, 2015
16:01 EDTGILDOptions Update; March 19, 2015
Subscribe for More Information
09:08 EDTGILDNew Gilead HIV drug likely to be approved in mid-2015, says Argus
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use